News

The latest news and views from bridge therapeutics

11/07/18 Dr. Steven Passik Has Joined the Scientific Advisory Board of Bridge Therapeutics

Steve Passik PhD, a recognized leader and researcher in pain management and addiction joins Bridge Therapeutics Scientific Advisory Board.

November 7, 2018

Dr. Passik has been a Principal Investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organizations. The intersection of pain and addiction has been the focus for much of his teaching activities and peer reviewed articles. He has written extensively on the treatment of cancer and AIDS patient’s pain management.

Read full article here

11/02/18 Bridge Therapeutics Announces the Addition of Dr. Bob Rappaport to Its Scientific Advisory Board

As their newest member, Dr. Bob Rappaport brings decades of drug approval experience to Bridge Therapeutics’ Scientific Advisory Board. 

November 2, 2018 

Dr. Rappaport spent 20 years at the Food and Drug Administration, with the last 12 years as Director of the Anesthesia, Analgesia, and Addiction Products Division at the Center for Drug Evaluation and Research. There he oversaw the approvals of drug products for that sector. Prior to his retirement, Dr. Rappaport received the FDA Lifetime Achievement Award.

Read the full article here

10/31/18 Bridge Therapeutics is Selected as a Finalists for the RESI 2018 Innovation Challenge

Bridge Therapeutics will present a poster presentation at the RESI Conference November 4, 2018, in New York.

October 31, 2018

Bridge Therapeutics has been selected by Life Science Nation’s internal scientific review board to be part of the Innovation Challenge presenting its technology in an exhibition-style format throughout the full-day RESI Conference on November 4, 2018, in New York. Being a Finalist gains Bridge additional exposure to investors and potential partners by showcasing its company and products through a dedicated poster in the Exhibit Hall.

Read the full article here

 

10/18/18 Panel: Buprenorphine ‘Can Give Patients Their Lives Back’

Ruth Potee, M.D., of Greenfield, Mass., said that when buprenorphine first became available in 2002, there was an expectation that it would be widely used in primary care because addiction is a chronic condition. “By 2010, only 2 percent of primary care physicians were prescribing it,” she said. “That was a massive failure.”

October 16, 2018 

Dr. David O’Gurek, associate professor in the Department of Family and Community Medicine at the Lewis Katz School of Medicine at Temple University of Philadelphia said stigma is one of the challenges of overcoming substance abuse disorder. He said buprenorphine can help by giving people more control.

Read the full article here

09/21/18 Dr. Bob Raffa Joins Bridge Therapeutics’ Scientific Advisory Board Bringing Decades of Research and Experience

Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. 

September 21, 2018 

Dr. Raffa is a global leader in pharmacology, with over 40 years of preclinical research on drug abuse and analgesic drug discovery. He has held many prestigious leadership roles, including Co-Leader for analgesic drug discovery at Johnson & Johnson where he attained the level of Research Fellow, as well as being Professor Emeritus at Temple University School of Pharmacy.

Read the full article here

09/04/18 Bridge Therapeutics Team to Speak on Tackling a Key Source of the Opioid Crisis

Dr. Greg Sullivan, Chief Scientific Officer, Dr. Dave Bergstrom. Chief Operations Officer, and Tim Peara of will be speaking about how Bridge Therapeutics’ lead investigational drug could be a key part of ending the opioid crisis.

September 4, 2018

Each year 70 million Americans will take an opioid for pain. Of these, 17 million take a strong opioid daily. It is these 17 million patients who are most at risk of addiction disorders leasing to shattered relationships, overdoes, and possibly death. 70% of opioid overdose victims started by abusing pain medication. A key part to ending the Opioid Crisis will be providing a safer therapy than opioids for chronic pain.

Read the full article here

08/21/18 Medication-Assisted Treatments Underused in Patients With Opioid Use Disorder

“A great part of the tragedy of this opioid crisis is that, unlike in previous such crises America has seen, we now possess effective treatment strategies that could address it and save lives,” Nora Volkow, MD, the director of the National Institute on Drug Abuse, wrote in an editorial accompanying the study (Ann Intern Med 2018 Jun 19). “Yet tens of thousands of people die each year because they have not received these treatments.”  

August 20, 2018 

According to the National Institutes of Health–funded study, adults prescribed buprenorphine had a decreased mortality rate of 38%, compared with patients not receiving any medication-assisted treatment over the one-year study period.

Read the full article here

08/17/18 To fight the opioid crisis, the US needs to look at what works

In this article the Washington Examiner discusses how buprenorphine/naloxone combination should be readily available and could act as a key defense against the on going opioid problem in the U.S.

August 16, 2018

Key to understanding how buprenorphine helps is an understanding of the difference between physical dependence and addiction. This can be a confusing distinction, as the terms are sometimes used interchangeably. Addiction is essentially an uncontrollable craving and an inability to control use. Dependence, on the other hand, is the term used to describe the physical reliance on opioids.

Read full article here

07/24/18 Expanding primary care buprenorphine treatment could curb opioid overdose crisis

In this article “Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities,” Sarah Wakeman, MD, medical director of the Massachusetts General Hospital Substance Use Disorders Initiative and Michael Barnett, MD, of the Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, discuss how “to have any hope of stemming the overdose tide, we have to make it easier to obtain buprenorphine than to get heroin and fentanyl”. The authors believe “there’s a realistic, scalable solution for reaching the millions of Americans with opioid use disorder: mobilizing the primary care physician (PCP) workforce to offer office-based addiction treatment with buprenorphine, as other countries have done.”

July 4, 2018

Expanding the availability of medication treatment for opioid use disorder in primary care settings would be a major step toward reducing overdose deaths, write the two physicians specializing in addiction medicine and health care delivery in the July 5 issue of New England Journal of Medicine.

Read the full article here

07/20/18 How a brain gets hooked on opioids

In this article by PBS explains how traditional opioids interact with the receptors in the brain to produce analgesia (pain relief), constipation, depression, and euphoria. Cathy Cahill PhD, a pain researcher at UCLA also explains how those with chronic pain taking traditional opioids experience big swings of emotion due to the euphoria and subsequent dysphoria as the opioids enter and leave the receptors.  The changes in emotions when coupled with mental health can make a patient more vulnerable to opioid addiction.

October 9, 2017

A 2017 study found most patients — 81 percent — whose addiction started with a chronic pain problem also had a mental health disorder. Another study found patients on morphine experience 40 percent less pain relief from the drug if they have mood disorder.

Read the full article here

123

For more information about Bridge Therapeutics please contact us today using the form below.